|Dr. Raj Mehra J.D., Ph.D.||Founder, Chairman, CEO & Pres||854.73k||N/A||1960|
|Mr. Michael J. Golembiewski||Chief Financial Officer||454.83k||N/A||1972|
|Ms. Kimberly Farrand||Sr. Director of Clinical Devel. & Operations||N/A||N/A||N/A|
|Mr. Anthony Marciano||Chief Communications Officer||N/A||N/A||N/A|
|Gopal Krishna Ph.D.||Head of Manufacturing & Technical Operations||N/A||N/A||N/A|
|Tim Whitaker M.D.||Chief Medical Officer||N/A||N/A||N/A|
|Ms. Karen Fusaro||Sr. VP & Head of Clinical Operations||N/A||N/A||N/A|
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, a peptidic inhibitor to treat patients with PD; SLS-008 for the treatment of pediatric indications; SLS-004 for the treatment of PD; SLS-010, an H3 receptor antagonist; and SLS-012. The company was founded in 2016 and is headquartered in New York, New York.
Seelos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.